Tissue Banking — Storing Biospecimens for Cancer Research

Tissue banking, also referred to as biospecimen biorepository storage, is the formal practice of collecting human biological materials and associated clinical data for scientific investigation. Samples are harvested during routine diagnostic biopsies or surgical resections, ensuring that patient care is never compromised. Once collected, tissues are typically frozen in liquid nitrogen or preserved as formalin-fixed paraffin-embedded blocks to protect cellular structure and genetic integrity.

These biobanks operate under rigorous ethical, legal, and quality-control standards. Robust governance frameworks ensure patient privacy through pseudonymisation or anonymisation. Scientists utilise banked specimens to examine molecular pathways, validate diagnostic assays, and understand mechanisms of therapy resistance across diverse patient cohorts over extended timeframes.

Donating to a tissue bank contributes directly to advancements in oncology that may benefit future individuals facing a similar diagnosis. For certain patients, banked tissue can also be re-analysed years later if new molecular tests emerge that inform their own treatment options. Participating gives patients an opportunity to support clinical science without requiring extra invasive procedures. Understanding biobanking helps individuals make informed decisions about consent and appreciate how past tissue donations have shaped the targeted medicines and clinical trials available to them today.

While tissue banking is not a diagnostic test in itself, it provides the substrate for diverse laboratory evaluations. Banked specimens undergo next-generation sequencing, immunohistochemistry, and transcriptomic profiling. These analyses identify actionable biomarkers such as EGFR mutations, ALK rearrangements, or microsatellite instability, linking laboratory discoveries directly back to clinical diagnostics and precision medicine.

Tissue banking applies to virtually all malignant diseases. It is especially prominent in breast cancer, lung cancer, colorectal cancer, and high-grade brain tumours such as glioblastoma, where tissue heterogeneity is pronounced. It also plays an indispensable role in rare malignancies, including soft tissue sarcomas and paediatric neuroblastoma, where individual centres see few cases and aggregated international biospecimen collections are essential to conduct meaningful translational research.

Banked biospecimens accelerate the development of systemic therapies, including antibody-drug conjugates, molecularly targeted small-molecule inhibitors, and immunotherapies. By studying banked tumours that developed drug resistance, pharmaceutical scientists can identify escape pathways and design secondary targeted agents. Banked tissue also facilitates retrospective translational studies linked to clinical trials, validating predictive biomarkers that indicate which patients benefit most from specific drug regimens.